Clinical performance of an IGF1 LC-MS/MS assay and associated normative dataset in routine endocrinology
European Journal of Endocrinology · 04.03.2026 · 194 (3) · 347-356
DOI: 10.1093/ejendo/lvag040 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Endocrinology, online erschienen am 27.02.2026. Verfasst von Michel J Vos und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Insulin-Like Growth Factor I, Tandem Mass Spectrometry, Liquid Chromatography-Mass Spectrometry, Endocrinology. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer, Dutch Ministry of Health, Welfare and Sport, University Medical Center Groningen.
Abstract (Originalsprache)
Background
Accurate interpretation of insulin-like growth factor-1 (IGF1) requires both analytically robust measurement and appropriate reference data. Most available IGF1 normative datasets are based on ligand-binding assays (LBA), limiting their applicability to liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods that provide higher analytical specificity.
Objective
To evaluate the clinical performance of an in-house developed LC-MS/MS IGF1 assay in combination with a method-matched normative dataset derived from the Dutch Lifelines cohort, and to compare it with a commonly used LBA.
Methods
Paired IGF1 results (n = 2057) were obtained using LC-MS/MS and the IDS iSYS LBA. Standard deviation scores (SDS) were calculated using assay-specific normative datasets. Agreement was assessed by regression, Bland-Altman, and weighted Cohen's κ analyses. Clinical validity was evaluated by comparing extreme SDS values with diagnostic categories adjudicated by endocrinologists.
Results
The LC-MS/MS method showed a proportional bias of −27% versus IDS iSYS and yielded symmetrically distributed SDS around zero, whereas IDS iSYS results were positively skewed. Categorical agreement was fair (κ = 0.39). LC-MS/MS-derived SDS corresponded more closely with clinical diagnoses across adult and pediatric groups, including acromegaly, growth hormone (GH) deficiency, and GH replacement therapy.
Conclusions
Our LC-MS/MS IGF1 assay integrated with its own population-based normative dataset demonstrated superior alignment with clinical assessment compared with LBA results. In our setting, this method provides a clinically reliable benchmark for IGF1 interpretation and may serve as a reference for IGF1 harmonization and broader adoption of the Lifelines normative dataset in routine endocrinology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
- Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
- Central Diagnostic Laboratory, University of Utrecht, Utrecht Medical Center, Utrecht, The Netherlands.
- Division of Endocrinology, Department of Paediatrics, Beatrix Children's Hospital, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
ORCID-Profile: Michel J Vos, Mark R Postma, Gianni Bocca, André P van Beek, Martijn van Faassen
Förderung
- Pfizer
- Dutch Ministry of Health, Welfare and Sport
- University Medical Center Groningen
- University of Groningen
Zitieren
APA
Vos, M. J., Postma, M. R., Lentjes, E. G., Habich-Reijntjes, L., Kelly, D., Muller Kobold, A., Bocca, G., van der Klauw, M. M., van Beek, A. P., Kema, I. P., & van Faassen, M. (2026). Clinical performance of an IGF1 LC-MS/MS assay and associated normative dataset in routine endocrinology. European Journal of Endocrinology, 194(3), 347-356. https://doi.org/10.1093/ejendo/lvag040
Vancouver
Vos MJ, Postma MR, Lentjes EG, Habich-Reijntjes L, Kelly D, Muller Kobold A, et al. Clinical performance of an IGF1 LC-MS/MS assay and associated normative dataset in routine endocrinology. European Journal of Endocrinology. 2026;194(3):347-356. doi:10.1093/ejendo/lvag040
BibTeX
@article{Vos2026,
author = {Vos, Michel J and Postma, Mark R and Lentjes, Eef G and Habich-Reijntjes, Lisanne and Kelly, Dylan and Muller Kobold, Anneke and Bocca, Gianni and van der Klauw, Melanie M and van Beek, André P and Kema, Ido P and van Faassen, Martijn},
title = {Clinical performance of an IGF1 LC-MS/MS assay and associated normative dataset in routine endocrinology},
journal = {European Journal of Endocrinology},
year = {2026},
volume = {194},
number = {3},
pages = {347--356},
doi = {10.1093/ejendo/lvag040}
}
EUVIMED